Objectives: It is widely assumed that, at matched transfusional iron- loading rates, responses to chelation therapy are similar, irrespective of the underlying condition. However, data are limited for rare transfusion- dependent anaemias, and it remains to be elucidated if response differs, depending on whether the anaemia has a primary haemolytic or production mechanism. Methods: The efficacy and safety of deferasirox (Exjade (R)) in rare transfusion-dependent anaemias were evaluated over 1 yr, with change in serum ferritin as the primary efficacy endpoint. Initial deferasirox doses were 10-30 mg/kg/d, depending on transfusion requirements; 34 patients had production anaemias, and 23 had haemolytic anaemias. Results : Patients with product...
OBJECTIVES/METHODS: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
Objectives/methods: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
Background: Reductions in transfusion requirements/improvements in hematologic parameters have been...
Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to che...
It is widely assumed that, at matched transfusional iron-loading rates, responses to chelation thera...
Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to che...
Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to che...
It is widely assumed that, at matched transfusional iron-loading rates, responses to chelation thera...
Background Following a clinical evaluation of deferasirox (Exjade) it was concluded that, in additio...
Background Following a clinical evaluation of deferasirox (Exjade (R)) it was concluded that, in add...
Objectives/methods: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
Introduction: Iron overload is the primary cause of mortality and morbidity in thalassemia major (TM...
Because of insufficient erythropoiesis, peripheral hemolysis and increased gastrointestinal iron abs...
Nontransfusion-dependent thalassemia (NTDT) patients may develop iron overload and its associated co...
OBJECTIVES/METHODS: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
OBJECTIVES/METHODS: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
Objectives/methods: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
Background: Reductions in transfusion requirements/improvements in hematologic parameters have been...
Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to che...
It is widely assumed that, at matched transfusional iron-loading rates, responses to chelation thera...
Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to che...
Objectives: It is widely assumed that, at matched transfusional iron-loading rates, responses to che...
It is widely assumed that, at matched transfusional iron-loading rates, responses to chelation thera...
Background Following a clinical evaluation of deferasirox (Exjade) it was concluded that, in additio...
Background Following a clinical evaluation of deferasirox (Exjade (R)) it was concluded that, in add...
Objectives/methods: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
Introduction: Iron overload is the primary cause of mortality and morbidity in thalassemia major (TM...
Because of insufficient erythropoiesis, peripheral hemolysis and increased gastrointestinal iron abs...
Nontransfusion-dependent thalassemia (NTDT) patients may develop iron overload and its associated co...
OBJECTIVES/METHODS: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
OBJECTIVES/METHODS: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
Objectives/methods: This 1-yr prospective phase II trial evaluated the efficacy of deferasirox in re...
Background: Reductions in transfusion requirements/improvements in hematologic parameters have been...